Cerus (CERS) Projected to Post Quarterly Earnings on Tuesday

Cerus (NASDAQ:CERS) is expected to issue its quarterly earnings data after the market closes on Tuesday, March 4th. Analysts expect Cerus to post earnings of ($0.01) per share and revenue of $52.95 million for the quarter. Parties that are interested in participating in the company’s conference call can do so using this link.

Cerus (NASDAQ:CERS) last announced its earnings results on Thursday, February 20th. The biotechnology company reported ($0.01) earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of ($0.01). Cerus had a negative net margin of 11.60% and a negative return on equity of 40.55%. The firm had revenue of $50.81 million during the quarter, compared to analyst estimates of $50.81 million. On average, analysts expect Cerus to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.

Cerus Stock Down 0.6 %

CERS stock opened at $1.64 on Tuesday. The firm’s 50-day moving average is $1.74 and its two-hundred day moving average is $1.83. The company has a market capitalization of $304.56 million, a price-to-earnings ratio of -14.91 and a beta of 1.29. Cerus has a 52 week low of $1.38 and a 52 week high of $2.59. The company has a current ratio of 2.59, a quick ratio of 1.92 and a debt-to-equity ratio of 1.19.

Analyst Ratings Changes

Separately, Cantor Fitzgerald reissued an “overweight” rating and set a $4.00 target price on shares of Cerus in a report on Friday.

Insiders Place Their Bets

In other news, Director Eric Bjerkholt sold 20,000 shares of the firm’s stock in a transaction dated Thursday, December 12th. The shares were sold at an average price of $1.78, for a total transaction of $35,600.00. Following the completion of the transaction, the director now owns 162,133 shares in the company, valued at approximately $288,596.74. This trade represents a 10.98 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. 3.40% of the stock is owned by company insiders.

About Cerus

Cerus Corporation operates as a biomedical products company. The company focuses on developing and commercializing the INTERCEPT Blood System to enhance blood safety. Its INTERCEPT Blood System, a proprietary technology for controlling biological replication that is designed to reduce blood-borne pathogens in donated blood components intended for transfusion.